133831-27-3

Basic information

• Product Name: Benzoic acid, 4-[2-(dimethylamino)ethenyl]-3-nitro-, methyl ester
• CAS NO: 133831-27-3
• Molecular Formula: C12H14N2O4
• Molecular Weight: 250.254
• Mol File: 133831-27-3.mol

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[2-(dimethylamino)ethenyl]-3-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[2-(dimethylamino)ethenyl]-3-nitro-, methyl ester(133831-27-3)
• EPA Substance Registry System: Benzoic acid, 4-[2-(dimethylamino)ethenyl]-3-nitro-, methyl ester(133831-27-3)

Safety Data

• Hazardous Substances Data: 133831-27-3(Hazardous Substances Data)

Upstream product

• 127-19-5 N,N-dimethyl acetamide 
• 7356-11-8 4-methyl-3-nitro-benzoic acid methyl ester 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 96-98-0 4-methyl-3-nitrobenzoic acid 

Downstream Products

• 153813-69-5 methyl 4-formyl-3-nitrobenzoate 
• 146667-95-0 2,2-dimethoxy-1-(4-methoxycarbonyl-2-nitrophenyl)ethane 

Relevant articles and documents

COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES

Therapeutic combinations of hepatitis B virus (HBV) vaccines and a pyridopyrimidine derivative are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the disclosed therapeutic combinations are also described. The invention provides therapeutic combinations or compositions and methods for inducing an immune response against hepatitis B viruses (HBV) infection.

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION

This invention relates to new benzazepine dicarboxamide compounds of the formula (I) wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS

This invention relates to new benzazepine carboxamide compounds of the formula (i) wherein X and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR8 agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION

This invention relates to new benzazepine dicarboxamide compounds of the formula (I) wherein R1 to R 3 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

NEW SPIRO[3H-INDOLE-3,2′-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS

The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.

Benzazepine Dicarboxamide Compounds

This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

Synthesis and biological activities of novel indole derivatives as potent and selective PPARγ modulators

Starting from the structure of Telmisartan, a new series of potent and selective PPARγ modulators was identified. The synthesis, in vitro and in vivo evaluation of the most potent compounds are reported and the X-ray structure of compound 7b bound to the PPARγ ligand binding domain is described.

SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION

Compounds of the formula wherein R1, R1', R2, R2' R4, R5, R6 and R7 are as described herein; as well as pharmaceutically acceptable prodrugs or salts of acidic compounds of formula I with bases and or basic compounds of formula I with acids are antiprolif